AstraZeneca PLC - American Depositary Shares (AZN)
87.48
+0.00 (0.00%)
NASDAQ · Last Trade: Nov 11th, 9:28 AM EST
Detailed Quote
Previous Close
87.48
Open
-
Bid
87.83
Ask
87.87
Day's Range
N/A - N/A
52 Week Range
61.24 - 87.53
Volume
27,058
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
1.030 (1.18%)
1 Month Average Volume
4,452,531
Chart
About AstraZeneca PLC - American Depositary Shares (AZN)
AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and manufacturing of a wide range of prescription medications. The company's primary areas of expertise include oncology, respiratory diseases, cardiovascular systems, and immunology, with a commitment to advancing innovative treatments that improve patient outcomes. AstraZeneca collaborates with healthcare professionals, researchers, and academic institutions to drive scientific advancements and ensure that their therapies reach those in need. Through its extensive portfolio, the company aims to address some of the world’s most pressing health challenges while maintaining a strong emphasis on sustainability and corporate responsibility. Read More
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable tension between investor optimism and concerns over valuation. As of November 2025, the AI market stands at a pivotal juncture, with a concentrated surge in mega-cap AI players driving overall market [...]
AstraZeneca's Baxdrostat cut blood pressure by 14 mmHg in the Phase 3 Bax24 trial, showing strong efficacy and safety in resistant hypertension patients.
Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.1 Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events.2-4
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results that are validating extensive research and development efforts across the industry. Investors are demonstrating a renewed appetite for risk,
Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in hypereosinophilic syndrome (HES),1 a rare disease driven by elevated eosinophils.2 These data will be presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, Florida.
After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto markets.
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design (IPD) has successfully leveraged AI to design antibodies from scratch, achieving unprecedented atomic precision. This groundbreaking development, primarily driven by a sophisticated generative AI model [...]
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central theme at the recent Quarter Century Update conference, where leading experts like Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, illuminated how AI is [...]
Snowflake Inc. & SAP SE collaborate to integrate their AI and business data clouds, providing faster access to reliable data and streamlining decision-making.
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly enhances the precision of drug development from initial discovery to commercial manufacturing. This fundamental shift is giving rise to the "TechBio" era, where AI is no longer merely a supporting tool but the [...]
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of excipient development. These "inactive" ingredients, which constitute the bulk of most drug formulations, are now at the forefront of an AI-driven innovation wave. By leveraging advanced [...]
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late 2025, an established force, fundamentally reshaping drug development and operational workflows. This shift is not merely incremental but a comprehensive revolution, accelerating Research & [...]
Paris, France – October 24, 2025 – Pharmaceutical giant Sanofi (EURONEXT: SAN, NASDAQ: SNY) saw its shares climb today following the announcement of stellar third-quarter 2025 financial results, largely fueled by the continued blockbuster performance of its immunology drug, Dupixent. The drug's sales have surged, with global figures reaching an unprecedented €4.
